

Brucellosis

PATIENT DEMOGRAPHICS		
		Pirth data: / / Aga:
Name (last, first): Address (mailing):		Birth date:/ Age: Sex: □Male □Female □Unk
, , ,		Ethnicity: Not Hispanic or Latino
Address (physical): City/State/Zip:		☐Hispanic or Latino ☐Unk
City/State/Zip: Phone (home): Phone (work/cell):		
Alternate contact: □Parent/Guardian □Spouse □Other		Race: □White □Black/Afr. Amer. (Mark all □Asian □Am. Ind/AK Native
Name: Phone:		that apply)
	none	
INVESTIGATION SUMMARY		Establish MAVEDCC2 Tives The Title
Local Health Department (Jurisdiction):		Entered in WVEDSS? □Yes □No □Unk
Investigation Start Date: / / Earliest date reported to LHD://		Case Classification:
Earliest date reported to DIDE://		☐ Confirmed ☐ Probable ☐ Suspect ☐ Not a case ☐ Unknown
REPORT SOURCE/HEALTHCARE PROVIDER (HCP)		
Report Source: Laboratory		
Reporter Name: Reporter Phone:		
Primary HCP Name:Primary HCP Phone: CLINICAL		
		Recovery date: / /
Clinical Findings and Symptoms	Complications	
☐ ☐ Fever (Highestmeasured temperature:°F)	☐ ☐ ☐ Miscarriage or stillbirth	
□ □ Night sweats		
□ □ □ Arthralgia	Hospitalization	
□ □ □ Headache	YNÜ	
□ □ □ Fatigue	□ □ Patient hospitalized for this illness	
□ □ Anorexia	If yes, hospital name:	
□ □ □ Myalgia	Admit date:// Discharge date: /_/	
□ □ □ Weight loss		
□ □ □ Endocarditis	Death	
□ □ □ Orchitis	YNU	
□ □ Epididymitis	☐ ☐ Patient died due to this illness	
□ □ Hepatomagaly	If yes, date of death: /_/	
□ □ Splenomegaly		
□ □ Arthritis		
☐ ☐ Meningitis	TDE ATMENIT	
□ □ □ Spondylitis	TREATMENT	
	YNU ☐ ☐ ☐ Prophylaxis given prior	to illness onset
	☐ ☐ ☐ Patient received antibiotic therapy due to this infection	
	If yes, specify:	one merupy due to this infection
	Type:	Duration:days
LABORATORY (Please submit copies of <u>all</u> labs to DIDE)		<u> </u>
YNU		
□ □ Culture and identification of <i>Brucella</i> spp. from clinical specimen		
□ □ Evidence of a four-fold or greater rise in <i>Brucella</i> antibody titer between acute- and convalescent-phase serum specimens obtained ≥2		
weeks apart		
□ □ Brucella total antibody titer of ≥ 160 by standard tube agglutination test (SAT) or Brucella microagglutination test (BMAT) in one or more serum specimens obtained after onset of symptoms		
□ □ Detection of Brucella DNA in a clinical specimen by PCR assay		

INFECTION TIMELINE Exposure period Onset date Instructions: Enter onset date in grey box. Count -60 Days from onset backward to determine (Max Incubation) (Min Incubation) probable exposure period Calendar dates: **EPIDEMIOLOGIC EXPOSURES (based on the above exposure period)** ☐ ☐ History of travel during exposure period (if yes, complete travel history below): **Destination (City, County, State and Country)** Arrival Date Departure Date **Reason for Travel** Y N U YNU ☐ ☐ Any contact with animal products ☐ ☐ ☐ Any contact with animals at home or elsewhere Source: □Cattle/cow/calf □Goat □Sheep □Other:_____ If yes: □Cattle/cow/calf □Goat □Sheep □Other:_____ Type of product: _____ Type of contact: Date of most recent contact: / / Type of contact: Date of most recent contact: // Location of most recent contact: Location of most recent contact: ___ □ □ Consumed unpasteurized dairy products (milk, cheese, etc) □ □ □ Travel outside of United States Source: □Cattle/cow/calf □Goat □Sheep □Other:____ Type of product: □ □ □ Foreign arrival (e.g. immigrant, adoptee, etc) Most recent consumption date: __/_/ _____ If yes, country: Location of where obtained: ☐ ☐ ☐ Case or household member lives on or works on farm ordairy ☐ ☐ Employed as a veterinarian oranimal technician ☐ ☐ ☐ Employed as an agricultural worker □ □ Employed as a laboratory worker ☐ ☐ ☐ Parenteral or mucous membrane *Brucella* vaccine exposure If yes, exposures source: □Specimen□Isolate □Other:_ If yes, type: \square S19 \square RB51 \square Rev1 If yes, was PEP initiated? ☐Yes ☐No ☐Unknown If yes, was PEP initiated? ☐Yes If yes to PEP, type and duration: ____ □No □Unknown If yes to PEP, type and duration: Where did exposure most likely occur? County: Country: **PUBLIC HEALTH ISSUES PUBLIC HEALTH ACTIONS** Y N U Y N U □ □ □ Case donated blood products, organs or tissue □ □ □ Notification of blood or tissue bank in the 30 days prior to symptom onset □ □ □ Disease education and prevention information provided to patient Date:__/__/ and/or family/guardian Agency/location:_____ ☐ ☐ ☐ Follow up with laboratorians exposed to specimen Type of donation: □ □ Notify patient obstetrician □ □ Pregnant (due date: _/_/___) □ □ □ Laboratory isolates forwarded to OLS □ □ □ Case knows someone who had shared exposure and is ☐ ☐ ☐ Outreach provided to employer to reduce employee risk currently having similar symptoms ☐ ☐ ☐ Facilitate laboratory testing of other symptomatic persons who have ☐ ☐ Epi link to another confirmed case of same condition a shared exposure ☐ ☐ ☐ Case is part of an outbreak □ □ □ Patient is lost to follow-up □ □ □ Other: □ □ □ Other: **WVEDSS** YNU □ □ Entered into WVEDSS (Entry date: __ / __/__ **Case Status:** ☐ Confirmed ☐ Probable ☐ Suspect ☐ Not a case ☐ Unknown **NOTES**